Ryvu Therapeutics is an oncology R&D company. The two most advanced assets in clinical development are SEL24, a dual PIM/FLT3 inhibitor out-licensed to Menarini Group, and wholly owned SEL120, a selective CDK8 inhibitor. Ryvu also has a diversified preclinical R&D pipeline.
Selvita has split into two separate companies. Selvita will continue trading as Ryvu Therapeutics, a newly introduced brand, and will fully focus on innovative drug discovery and development. Selvita CRO, drug discovery services, was spun out into a separate listed entity. We believe both businesses have sufficient momentum to sustain the split. Ryvu Therapeutics R&D pipeline is progressing according to plan and two clinical trials with SEL24 and SEL120 could deliver data over 2019–20. The lead product is SEL120, a CDK8 inhibitor, partnered with the Leukemia & Lymphoma Society for AML. SEL120 is being explored in a Phase Ib trial in AML and HR-MDS with the first patient recruited in September 2019. SEL24 is a dual PIM/FLT3 inhibitor in Phase I/II for AML out-licensed to Menarini in March 2017.
The profiles of SEL24 and SEL120 are potentially unique compared to existing clinical-stage competitors and both candidates may offer efficacy advantages.